Table 3 Clinical response to trastuzumab combined chemotherapy.

From: PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma

(A)

Variables

PTEN loss

PTEN Positive

p valuea

n = 29

n = 116

n

N

Clinical response

0.114

CR

0 (0%)

3 (3%)

 

PR

10 (34%)

49 (42%)

 

SD

4 (14%)

33 (28%)

 

Non-CR/non-PD

7 (24%)

15 (13%)

 

PD

8 (28%)

16 (14%)

 

Disease control rateb

21 (72%)

100 (86%)

0.094

Response ratec

10 (34%)

52 (45%)

0.402

(B)

Variables

PTEN loss

PTEN Positive

p valuea

n = 21

n = 97

n

N

Clinical response

0.142

CR

0 (0%)

2 (2%)

 

PR

10 (48%)

49 (51%)

 

SD

4 (19%)

33 (34%)

 

PD

7 (33%)

13 (13%)

 

Disease control rated

14 (67%)

84 (87%)

0.049

Response ratec

10 (48%)

51 (53%)

0.811

(C)

Variables

PTEN loss

PTEN positive

p valuea

Months

Months

Duration of stable diseasee

Mean (SD)

8.3 (7.9)

13.6 (14.7)

0.063

  1. (A). Objective response rate and disease control rate in 145 patients. (B). Objective response rate and disease control rate in 118 patients with target lesions. (C). Duration of stable disease.
  2. CR complete response, PR partial response, SD stable disease, PD progressive disease.
  3. aFisher extract test was used for categorical items and Student’s t test was used for continuous variables, respectively.
  4. bDisease control rate: the sum of the proportion of CR and PR and SD and non-CR/non-PD in (A).
  5. cResponse rate: the proportion of complete response and partial response in (A) and (B).
  6. dDisease control rate: the sum of the proportion of CR and PR and SD in (B).
  7. eDuration of stable disease: the duration from the date when trastuzumab-combined therapy was first administered to the date when PD was determined.
Back to article page